<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0005110'>Atrial fibrillation</z:hpo> is the most common of the <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> and is associated with high risk of <z:hpo ids='HP_0001297'>stroke</z:hpo> and systemic <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Prevention of these complications is therefore a major component of clinical management in patients with this rhythm disorder </plain></SENT>
<SENT sid="2" pm="."><plain>The choice of antithrombotic therapy in any given patient depends on his or her risk profile and needs to be carefully balanced against the risk of <z:mp ids='MP_0001914'>bleeding</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In this review we discuss the pathophysiology of thrombogenesis in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, risk factors for systemic <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> in <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo>, patient risk stratification modules both for systemic <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> and the risk of <z:mp ids='MP_0001914'>bleeding</z:mp>, current antithrombotic therapy strategies, clinicoepidemiological evidence that led to their evolvement, the challenges that <z:e sem="disease" ids="C0032064" disease_type="Disease or Syndrome" abbrv="">plague</z:e> them, recent developments in the field and how they could possibly affect our future clinical decision making </plain></SENT>
</text></document>